D. Western Therapeutics Institute (FRA:6DW) Beneish M-Score: -3.05 (As of Jul. 07, 2026)


FRA:6DW D. Western Therapeutics Institute Inc FRA:6DW
22 GF Score
Price €0.39
GF Value €0.31
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is D. Western Therapeutics Institute Beneish M-Score?

D. Western Therapeutics Institute FRA:6DW -1.03% 22 Beneish M-Score is -3.05 as of Jul. 07, 2026. GuruFocus rates FRA:6DW with a GF Score™ of 22/100 and a GF Value™ of €0.31 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 824 Biotechnology companies, D. Western Therapeutics Institute ranks better than 76.09% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.05 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for D. Western Therapeutics Institute's Beneish M-Score or its related term are showing as below:

FRA:6DW' s Beneish M-Score Range Over the Past 10 Years
Min: -9.19   Med: -2.52   Max: -1.1
Current: -3.05

During the past 13 years, the highest Beneish M-Score of D. Western Therapeutics Institute was -1.10. The lowest was -9.19. And the median was -2.52.


D. Western Therapeutics Institute Beneish M-Score Historical Data

* Premium members only.

The historical data trend for D. Western Therapeutics Institute's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

D. Western Therapeutics Institute Beneish M-Score Chart

D. Western Therapeutics Institute Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.09 -2.46 -3.30 -2.39 -3.05

D. Western Therapeutics Institute Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.39 0.00 0.00 -3.05 0.00

FRA:6DW vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, D. Western Therapeutics Institute's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


D. Western Therapeutics Institute Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, D. Western Therapeutics Institute's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where D. Western Therapeutics Institute's Beneish M-Score falls into.


FRA:6DW
22GF Score
D. Western Therapeutics Institute Inc FRA:6DW
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

D. Western Therapeutics Institute Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of D. Western Therapeutics Institute for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9206+0.528 * 1.0011+0.404 * 0.5889+0.892 * 0.7251+0.115 * 0.9761
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * -0.063704-0.327 * 0.5993
=-3.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was €0.52 Mil.
Revenue was €2.12 Mil.
Gross Profit was €1.91 Mil.
Total Current Assets was €11.07 Mil.
Total Assets was €11.88 Mil.
Property, Plant and Equipment(Net PPE) was €0.05 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.26 Mil.
Selling, General, & Admin. Expense(SGA) was €0.00 Mil.
Total Current Liabilities was €1.12 Mil.
Long-Term Debt & Capital Lease Obligation was €2.77 Mil.
Net Income was €-3.46 Mil.
Gross Profit was €0.00 Mil.
Cash Flow from Operations was €-2.71 Mil.
Total Receivables was €0.78 Mil.
Revenue was €2.93 Mil.
Gross Profit was €2.64 Mil.
Total Current Assets was €9.16 Mil.
Total Assets was €10.37 Mil.
Property, Plant and Equipment(Net PPE) was €0.07 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.31 Mil.
Selling, General, & Admin. Expense(SGA) was €0.00 Mil.
Total Current Liabilities was €0.82 Mil.
Long-Term Debt & Capital Lease Obligation was €4.84 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.518 / 2.123) / (0.776 / 2.928)
=0.243994 / 0.265027
=0.9206

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2.637 / 2.928) / (1.91 / 2.123)
=0.900615 / 0.89967
=1.0011

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (11.065 + 0.051) / 11.883) / (1 - (9.16 + 0.069) / 10.365)
=0.064546 / 0.1096
=0.5889

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2.123 / 2.928
=0.7251

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.306 / (0.306 + 0.069)) / (0.26 / (0.26 + 0.051))
=0.816 / 0.836013
=0.9761

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 2.123) / (0 / 2.928)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.772 + 1.117) / 11.883) / ((4.836 + 0.824) / 10.365)
=0.327274 / 0.546068
=0.5993

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-3.462 - 0 - -2.705) / 11.883
=-0.063704

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

D. Western Therapeutics Institute has a M-score of -3.13 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.05 mean?
D. Western Therapeutics Institute (FRA:6DW) has a Beneish M-Score of -3.05 as of Jul. 07, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on D. Western Therapeutics Institute and its competitors. According to the industry distribution chart, D. Western Therapeutics Institute ranks #197 out of 824 companies in the Biotechnology industry, placing it in the top 23.9%.
Is D. Western Therapeutics Institute's Beneish M-Score too high?
D. Western Therapeutics Institute's current Beneish M-Score is -3.05. Based on the distribution chart, D. Western Therapeutics Institute ranks #197 out of 824 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, D. Western Therapeutics Institute has a GF Score™ of 22/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does D. Western Therapeutics Institute's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, D. Western Therapeutics Institute ranks #197 out of 824 companies for Beneish M-Score. This places D. Western Therapeutics Institute in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on D. Western Therapeutics Institute and its competitors. D. Western Therapeutics Institute's current Beneish M-Score is -3.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D. Western Therapeutics Institute stock overvalued right now?
Based on GuruFocus' analysis, D. Western Therapeutics Institute (FRA:6DW) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.31, compared to a current price of €0.39 — trading 24.5% above its estimated fair value. The current Beneish M-Score is -3.05. D. Western Therapeutics Institute's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For D. Western Therapeutics Institute (FRA:6DW), the current Beneish M-Score is -3.05 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is D. Western Therapeutics Institute (FRA:6DW) Overvalued in 2026?

Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued. The current stock price of €0.39 is trading 24.5% above its estimated GF Value™ of €0.31. GuruFocus considers D. Western Therapeutics Institute to be Modestly Overvalued.

Key valuation signals for FRA:6DW:

  • Beneish M-Score: -3.05
  • GF Value™: €0.31 vs. price of €0.39 (24.5% above fair value)
  • GF Score™: 22/100 with 3 warning signs

No single metric tells the full story. See the FRA:6DW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


D. Western Therapeutics Institute Business Description

Other Exchanges 4576:Japan
Address 7th Floor, 18 KT Bulding, 1-18-11, Nishiki, Naka-ku, Aichi, Nagoyashi, JPN, 460-0003
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
22GF Score

Get the complete analysis for FRA:6DW

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.39
Price
€0.31
GF Value